Fig. 1 · Structure

Documents & Downloads

Cladribine

Cat. No. A10223 CAS 4291-63-8
Cladribine is a synthetic anti-cancer agent that mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, which interferes with the cell's ability to process DNA.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In stimulated human PBMCs, excess deoxycytidine prevented cladribine-induced inhibition of proliferation and early apoptosis, supporting a role for DCK-dependent activation in these cytotoxic responses. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Adenosine deaminase (MM1.S cells) 0.18 μM
Adenosine deaminase (RPMI8226 cells) 0.75 μM
Adenosine deaminase (U266 cells) 2.43 μM

Cellular Effect

Cell Line Activity Value Description Reference
BJ IC50 > 10 μM Cytotoxicity against human BJ cells after 3 days by MTT assay [PMID: 21711054]
BT-549 IC50 0.123 μM Cytotoxicity against human BT549 cells after 3 days by MTT assay [PMID: 21711054]
BV-173 IC50 0.0008 μM Cytotoxicity against human BV173 cells after 3 days by MTT assay [PMID: 21711054]
C6 IC50 9.07 μM Cytotoxicity against rat C6 cells after 3 days by MTT assay [PMID: 21711054]
CCRF-CEM IC50 0.0005 μM Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay [PMID: 21840722]
CT26 IC50 0.131 μM Cytotoxicity against mouse CT26 cells after 3 days by MTT assay [PMID: 21711054]
EL4 IC50 0.848 μM Cytotoxicity against mouse EL4 cells after 3 days by MTT assay [PMID: 21711054]
HCT-116 IC50 < 0.1 μM Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay [PMID: 29326016]
HCT-116 IC50 0.3 μM Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay [PMID: 28219046]
HCT-116 IC50 0.3 μM Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay [PMID: 25462277]
HCT-116 IC50 9.43 μM Cytotoxicity against human HCT116 cells after 3 days by MTT assay [PMID: 21711054]
HeLa IC50 > 10 μM Cytotoxicity against human HeLa cells after 3 days by MTT assay [PMID: 21711054]
HepG2 IC50 0.04 μM Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay [PMID: 29326016]
HPAC IC50 9.32 μM Cytotoxicity against human HPAC cells after 3 days by MTT assay [PMID: 21711054]
HT-29 IC50 9.44 μM Cytotoxicity against human HT-29 cells after 3 days by MTT assay [PMID: 21711054]
Huh-7 IC50 0.4 μM Antiproliferative activity against human HuH7 cells after 72 hrs by SRB assay [PMID: 29326016]
Huh-7 IC50 1.8 μM Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by SRB assay [PMID: 28219046]
Huh-7 IC50 1.8 μM Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay [PMID: 25462277]
K562 IC50 0.17 μM Cytotoxicity against human paclitaxel resistant K562 cells after 3 days by MTT assay [PMID: 21711054]
K562 IC50 10 μM Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay [PMID: 25960323]
K562 IC50 7.69 μM Cytotoxicity against human K562 cells after 3 days by MTT assay [PMID: 21711054]

21 records · Scroll to view more

Cladribine Research Summary

This section summarizes 3 in vitro studies of Cladribine from 2 published references.

Cladribine In Vitro Studies

Cladribine reduced T- and B-cell proliferation in PHA-stimulated PBMC cultures, while NK-cell proliferation was unaffected. A separate 16-hour experiment detected increased early apoptosis in T, B and NK populations. [1]

In cultured lymphocytes from eight MS patients and four controls, 5 nM cladribine for four days produced no detectable increase in mitochondrial DNA mutations. This exploratory result is limited to the tested exposure and assay sensitivity; it does not exclude other mitochondrial effects. [2]

Deoxycytidine rescue of PBMC proliferation

Cell-based study · Human PBMCs from healthy donors and relapsing-remitting MS patients; PHA-stimulated subsets; N = 10 reported for Figure 2. [1]

Cladribine impaired proliferation of T and B cells, but not NK cells; excess deoxycytidine prevented the inhibitory response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Percentage of cells with diluted CFSEQualitative comparison Reduced T- and B-cell proliferation; no NK-cell inhibition; rescue with deoxycytidine.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 or 1 μM cladribine; rescue conditions contained 250 μM deoxycytidine.
Exposure duration
PHA 0.25 μg/mL for 96 h; cladribine during the last 48 h; deoxycytidine pretreatment 30 min.
Method
CFSE dilution by flow cytometry; no-cladribine and deoxycytidine-only comparators; repeated-measures ANOVA with Dunnett comparisons.
Vehicle
Cladribine dissolved in DMSO, then diluted in complete medium.
Co-treatment
Deoxycytidine used as a competing DCK substrate; PHA supplied the proliferative stimulus.
Reported limits
Final DMSO percentage and explicit solvent matching are not stated in the read methods. Supplementary Figure S1 gating image not retrieved.
Methods and source locations

Compound reported in the paper: Cladribine; Compound label in the paper: 2-chlorodeoxyadenosine

Named cladribine in the reported culture system; supplier lot equivalence and clinical efficacy are not established.

Methods 2.3, 2.4.1, 2.6–2.7; Results 3.2; Figure 2 and caption (PDF p.6)

Percentage of cells with diluted CFSE: CFSE dilution by flow cytometry; no-cladribine and deoxycytidine-only comparators; repeated-measures ANOVA with Dunnett comparisons. — Methods 2.3, 2.4.1, 2.6–2.7; Results 3.2; Figure 2 and caption (PDF p.6)

Deoxycytidine rescue of early PBMC apoptosis

Cell-based study · Human PBMCs from healthy donors and relapsing-remitting MS patients; PHA-stimulated subsets; N = 10 reported for Figure 3. [1]

Cladribine increased early apoptosis in T, B and NK populations; deoxycytidine prevented this response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Annexin V-positive, 7AAD-negative cellsQualitative comparison Increased early apoptosis with cladribine; response abrogated by deoxycytidine.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 or 1 μM cladribine; rescue conditions contained 250 μM deoxycytidine.
Exposure duration
16 h with PHA 5 μg/mL; deoxycytidine pretreatment 30 min.
Method
Annexin V/7AAD flow cytometry; no-cladribine and deoxycytidine-only comparators; repeated-measures ANOVA with Dunnett comparisons.
Vehicle
Cladribine dissolved in DMSO, then diluted in complete medium.
Co-treatment
Deoxycytidine rescue; PHA stimulation.
Reported limits
Final DMSO percentage and explicit solvent matching not stated in the read methods. Supplementary Figure S2 gating image not retrieved.
Methods and source locations

Compound reported in the paper: Cladribine; Compound label in the paper: 2-chlorodeoxyadenosine

Named cladribine in the reported culture system; supplier lot equivalence and clinical efficacy are not established.

Methods 2.3, 2.4.2, 2.6–2.7; Results 3.3; Figure 3 and caption (PDF p.6)

Annexin V-positive, 7AAD-negative cells: Annexin V/7AAD flow cytometry; no-cladribine and deoxycytidine-only comparators; repeated-measures ANOVA with Dunnett comparisons. — Methods 2.3, 2.4.2, 2.6–2.7; Results 3.3; Figure 3 and caption (PDF p.6)

Mitochondrial DNA mutations after low-dose exposure

Cell-based study · PBMC cultures from eight relapsing MS patients and four healthy controls; CD4+, CD8+ and CD19+ populations separated after treatment. [2]

No detectable treatment-associated increase in mitochondrial DNA mutations was found in these cultured lymphocyte populations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mitochondrial DNA mutation rates and distributionQualitative comparison No detected difference between cladribine-treated and nontreated cells.[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 nM cladribine
Exposure duration
4 days after 1 day of conditioning.
Method
Next-generation mtDNA amplicon sequencing; untreated parallel cultures; Wilcoxon rank sum tests for Figure 5a,c and Student t-test for Figure 5b.
Vehicle
Not specified in the read original text.
Co-treatment
No other drug treatment reported for this experiment.
Reported limits
Supplier, lot, stock solvent and analytical form characterization are not specified in the retrieved original methods.
Methods and source locations

Compound reported in the paper: Cladribine; Compound label in the paper: 2-chlorodeoxyadenosine

Named cladribine in the reported culture system; supplier lot equivalence and clinical efficacy are not established.

Methods: Ex vivo sample collection, PBMC cultures, cell separation, next-generation sequencing, somatic mutation calling and Statistical analysis; Results: Somatic mutations in mtDNA in human cultured ex vivo lymphocytes; Figure 5 (advance-access PDF p.7; retained PDF page 8)

Mitochondrial DNA mutation rates and distribution: Next-generation mtDNA amplicon sequencing; untreated parallel cultures; Wilcoxon rank sum tests for Figure 5a,c and Student t-test for Figure 5b. — Methods: Ex vivo sample collection, PBMC cultures, cell separation, next-generation sequencing, somatic mutation calling and Statistical analysis; Results: Somatic mutations in mtDNA in human cultured ex vivo lymphocytes; Figure 5 (advance-access PDF p.7; retained PDF page 8)

Specifications

Manufacturer Adooq Bioscience
CAS Number 4291-63-8
Formula C10H12ClN5O3
Molecular Weight 285.7
Synonyms 2-chlorodeoxyadenosine; Leustatin
SMILES
C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(N=C3N)Cl)CO)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 52 mg/mL (182.01 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
5% DMSO+30% PEG 300+1% Tween 80+H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cladribine Research References

  1. [1] Nicolás Fissolo, Laura Calvo-Barreiro, Herena Eixarch, et al. Immunomodulatory Effects Associated with Cladribine Treatment Cells (2021). PMID: 34943995 DOI: 10.3390/cells10123488 Source material
  2. [2] Elina Järvinen, Fumi Suomi, James B Stewart, et al. Cultured lymphocytes’ mitochondrial genome integrity is not altered by cladribine Clinical and Experimental Immunology (2023). PMID: 37860849 DOI: 10.1093/cei/uxad112 Source material

Added to your cart

View Cart Checkout
Loading...